文献速递免疫规划卫生政策与健康促进

印度尼西亚轮状病毒疫苗接种的成本效果分析

Cost effectiveness analysis of rotavirus vaccination in Indonesia.
PubMed 文献 · Vaccine · 2024-11-04

本研究评估印度尼西亚将轮状病毒疫苗纳入国家免疫规划的成本效果,假设三剂次接种方案,先引入进口Rotavac®后分阶段使用国产疫苗,从卫生系统和社会视角分析。10年接种规划成本82.6百万美元,可预防7.3百万例轮状病毒病例和0.42百万伤残调整生命年,分阶段规划ICER为社会视角464美元/DALY、卫生部门视角479美元/DALY。

要点

  • 10年接种规划成本82.6百万美元,可预防7.3百万例轮状病毒病例和0.42百万DALY。
  • 社会视角分阶段规划ICER为464美元/DALY(人均GDP的12%)。
  • 卫生部门视角ICER为479美元/DALY(人均GDP的13%)。

核心结论

  • 将轮状病毒疫苗纳入国家免疫规划在印度尼西亚可能具有高度成本效果。

研究设计与样本

  • 研究为成本效果分析,假设三剂次疫苗接种方案,基于免疫战略咨询专家组提出的计划引入方案。
  • 分析包括先引入进口轮状病毒疫苗Rotavac®(印度Bharat Biotech)后分阶段实施国产轮状病毒疫苗(印度尼西亚Bio Farma),从卫生系统和社会视角进行评估。
  • 主要结局指标为与不接种相比每避免一个伤残调整生命年(DALY)的增量成本(2019年美元)。
  • 模型输入来自印度尼西亚疾病成本研究、国家信息系统和科学文献,涵盖疾病发病率、住院、死亡、医疗成本和疫苗相关因素。
  • 分析包括单变量和概率敏感性分析以评估各种参数。

主要发现

  • 10年疫苗接种规划的成本为82.6百万美元,可潜在预防7.3百万例轮状病毒病例和0.42百万DALY。
  • 社会视角下,分阶段规划的增量成本效果比(ICER)为每避免一个DALY 464美元(印度尼西亚人均国内生产总值的12%)。
  • 卫生部门视角下,ICER相似,为479美元(人均GDP的13%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rotavirus (RV) remains the most common cause of morbidity and mortality due to acute gastroenteritis (AGE) in children under five. In Indonesia, RV is responsible for 60 % of severe AGE and 40 % of non-severe AGE in these children. This study assessed the cost-effectiveness of introduction of rotavirus vaccines (RVV) into the National Immunization Program in Indonesia. METHODS: We conducted a cost-effectiveness analysis (CEA) of RVV introduction in Indonesia, assuming a three-dose vaccine schedule based on the planned introduction proposed by the Strategic Advisory Group of Experts on Immunization. The analysis involved an initial introduction of an imported RVV (Rotavac®, Bharat Biotech, India) followed by a staged implementation of the locally produced RVV (Bio Farma, Indonesia) from both health system and societal perspectives. The primary outcome measure was the incremental cost (2019 USD) per disability-adjusted life year (DALY) averted, compared to no vaccination. We took model inputs from an Indonesian cost-of-illness study, national information systems and scientific literature, covering disease incidence, hospitalization, mortality, healthcare costs, and vaccine related factors. Our analyses included univariate and probabilitistic sensitivity analyses to assess various parameters. FINDINGS: The cost of a 10-year vaccination program is 82.6 million USD and can potentially prevent 7.3 million cases of rotavirus and 0.42 million DALYs. From a societal perspective, the incremental cost-effectiveness ratio (ICER) for the staged program is 464 USD per DALY averted (12 % of Indonesia's gross domestic product (GDP) per capita). From a healthcare sector perspective, ICER is similar at 479 USD (13 % GDP per capita). INTERPRETATION: The introduction of RVV into the National Immunization Program is likely to be highly cost-effective in Indonesia. FUNDING: This work was supported by funding agreement with the Murdoch Children's Research Institute (MCRI), PATH, and the Indonesian Technical Advisory Group on Immunization (ITAGI).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Thobari JA, Watts E, Carvalho N, et al. Cost effectiveness analysis of rotavirus vaccination in Indonesia. Vaccine. 2024. PMID: 39500219. doi:10.1016/j.vaccine.2024.126478

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。